Observational studyMolecular genetics & genomic medicine2026
Apolipoprotein E DNA Methylation Linked to Cognitive Decline in Postmenopausal Women With Breast Cancer.
Observational study in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCognitive decline is common among individuals with breast cancer (BC), and carriage of the apolipoprotein E (APOE) ε4 allele increases risk. APOE DNA methylation (DNAm) may influence cognition through regulation of neuroinflammatory and amyloid-related pathways. Exercise is a potential factor affecting DNAm and cognition. This study examined associations between APOE DNAm and cognition in postmenopausal women with BC and evaluated moderation by APOE4 carriage status and exercise.
methodsData were drawn from a 6-month randomized trial of moderate-intensity exercise versus usual care. Cognition was assessed at baseline and 6 months, and change scores were calculated. APOE4 status (carrier, non-carrier) and baseline DNAm (M-value) were determined from peripheral blood. Regression models tested cross-sectional and longitudinal associations, adjusting for age and education. Moderation by APOE4 status and intervention group was also tested.
resultsAmong 102 participants, APOE DNAm was consistently suggestively associated with cognition. Higher DNAm at promoter-region CpGs (cg04406254, cg14123992, cg20051876) was linked to poorer cognition, with direction and magnitude differing by APOE4 status and group. APOE4 carriers with higher DNAm showed better cognitive performance, and exercisers with higher DNAm showed improved outcomes, suggesting exercise may buffer epigenetic effects.
conclusionsFindings may implicate APOE DNAm as a biomarker of cognition and highlight exercise supporting cognitive health in women with BC, although replication is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.